Aquilonius_1983_J.Neurol.Neurosurg.Psychiatry_46_929

Reference

Title : Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis - Aquilonius_1983_J.Neurol.Neurosurg.Psychiatry_46_929
Author(s) : Aquilonius SM , Eckernas SA , Hartvig P , Lindstrom B , Osterman PO , Stalberg E
Ref : Journal of Neurology Neurosurg Psychiatry , 46 :929 , 1983
Abstract :

Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.

PubMedSearch : Aquilonius_1983_J.Neurol.Neurosurg.Psychiatry_46_929
PubMedID: 6644317

Related information

Inhibitor Pyridostigmine

Citations formats

Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO, Stalberg E (1983)
Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis
Journal of Neurology Neurosurg Psychiatry 46 :929

Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO, Stalberg E (1983)
Journal of Neurology Neurosurg Psychiatry 46 :929